Ryufin

Genus plc

United Kingdom · GB0002074580 · reports in GBP · Europe

The answers

From the annual report for the year to Jun 30, 2025. Each line says what it is based on.

Is it growing?Fair
Revenue +0.6% in the year to Jun 30, 2025, on the year before.
Is it a good business?To watch
It earned 4.1% on its shareholders' equity in the year to Jun 30, 2025.
Is it safe?Good
Equity is 53% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Jun 30, 2025, consolidated, in GBP.

£673M

revenue

6.3%

operating margin

£19M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Jun 2022Jun 2023Jun 2024Jun 2025
Revenue£593M£690M£669M£673M
Operating profit£49M£41M£6M£42M
Net profit to shareholders£41M£33M£8M£19M
Earnings per share£0.63£0.51£0.12£0.29
Cash from operations−£67M−£31M£30M£67M
Capital spending£42M£26M£15M£13M
Cash£39M£36M£43M£48M
Total assets£1.0B£1.0B£988M£899M
Equity£572M£567M£514M£476M

What they do

In the company's own words, from the annual report.

We produce and sell elite animal genetics to farmers. Animals bred from these genetics have traits that farmers value, such as feed conversion efficiency, disease resistance and faster growth. Our genetics therefore enable farmers to raise healthier animals that produce more high-quality protein per unit of input. This increases farmer profitability and food supply resilience, and reduces the environmental impact of animal protein production.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.